Efficacy and safety of adalimumab in paediatric patients with moderate-to-severe ulcerative colitis (ENVISION I): a randomised, controlled, phase 3 study

In analysis (n=77;age 4-17 yrs), a significantly higher proportion were in partial Mayo score (PMS) remission at 8 wks with high-dose induction adalimumab vs placebo (60 vs 19.8%;p=0.0001) & similarly with full MS remission at wk 52 in 8 wk PMS responders (45 vs 18.4%;p=0.0001)

Source:

The Lancet Gastroenterology and Hepatology